Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 7, 2012, Pages 1131-1144

  Li, Na ^a,b   Zheng, Dawei ^b   Wei, Xiyin ^a   Jin, Ziliang ^a   Zhang, Cuicui ^a   Li, Kai ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b People's Hospital of Rushan   (China)

Author keywords

Circulating endothelial cells; Collagen coverage of tumor vessels; Matrix metalloproteinases; Rh endostatin; Vascular normalization

Indexed keywords

CD147 ANTIGEN; CISPLATIN; GELATINASE A; GELATINASE B; RECOMBINANT ENDOSTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; BLOOD VESSEL PERMEABILITY; CANCER COMBINATION CHEMOTHERAPY; CIRCULATING ENDOTHELIAL CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MICROVASCULAR DENSITY; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VASCULAR NORMALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; ENDOSTATINS; ENDOTHELIAL CELLS; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864344495     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1189-z     Document Type: Article

References (33)

1. Al-Dissi AN, Haines DM, Singh B et al (2010) Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas. Can Vet J 51(10):1109-1114
2. Asahara T, Masuda H, Takahashi T et al (1999a) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228 (Pubitemid 29377293)
3. Asahara T, Takahashi T, Masuda H et al (1999b) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18(14):3964-3972 (Pubitemid 29335849)
4. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95 (Pubitemid 46075199)
5. Beaudry P, Force J, Naumov GN et al (2005) Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11(9):3514-3522 (Pubitemid 40627906)
6. Bertolini F (2008) Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. Cancer Metastasis Rev 27(1):95-101
7. Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63(15):4342-4346 (Pubitemid 36951001)
8. Blann AD, Woywodt A, Bertolini F et al (2005) Circulating endothelial cells: Biomarker of vascular disease. Thromb Haemost 93(2):228-235 (Pubitemid 40253726)
9. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249-257
10. Chang YS, di Tomaso E, McDonald DM et al (2000) Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97(26):14608-14613 (Pubitemid 32016623)
11. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186
12. Furstenberger G, von Moos R, Lucas R et al (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94(4): 524-531 (Pubitemid 43289756)
13. Goon PK, Lip GY, Boos CJ et al (2006) Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8(2):79-88
14. Huang G, Chen L (2010) Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol 136(8): 1201-1211
15. Huang Y, Song N, Ding Y et al (2009) Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 69(19):7529-7537
16. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58-62 (Pubitemid 40093472)
17. Khan SS, Solomon MA, McCoy JP Jr (2005) Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64(1):1-8 (Pubitemid 40960406)
18. Li H, Raia V, Bertolini F et al (2008) Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 101(7):884-888 (Pubitemid 351347717)
19. Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of bonemarrow- derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7(11):1194-1201 (Pubitemid 33063774)
20. Mancuso P, Burlini A, Pruneri G et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97(11):3658-3661
21. Mancuso P, Calleri A, Cassi C et al (2003) Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 522: 83-97 (Pubitemid 36570529)
22. Ramalingam RR, Dahlberg SE, Langer CJ et al (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26(1):60-65
23. Reimers N, Zafrakas K, Assmann V et al (2004) Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10(10): 3422-3428 (Pubitemid 38685448)
24. Schuch G, Heymach JV, Nomi M et al (2003) Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63(23):8345-8350 (Pubitemid 37549488)
25. Shaked Y, Henke E, Roodhart JM et al (2008) Rapid chemotherapyinduced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14(3):263-273
26. Tong RT, Boucher Y, Kozin SV et al (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731-3736 (Pubitemid 38697278)
27. Wagner S, Fueller T, Hummel V et al (2003) Influence of VEGFR2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC). J Neurooncol 62(3): 221-231 (Pubitemid 36591957)
28. Wang J, Sun Y, Liu Y et al (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YHJ 16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 8(4):283-290 (Pubitemid 41206392)
29. Weichselbaum RR (2005) How does antiangiogenic therapy affect brain tumor response to radiation? Nat Clin Pract Oncol 2(5):232-233 (Pubitemid 40812448)
30. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147(1):9-19
31. Yuan J, Wu CW, Liu ZJ et al (2010) Observation of the antitumor effect of endostar combined with docetaxel under different administration sequences. Chin J Oncol 32(8):580-585
32. Zhen FS, Wang J, Liang J et al (2010) Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? Int J Exp Path 91:10-16
33. Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23(1-2): 101-117 (Pubitemid 38221598)